Literature DB >> 29554847

The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant Staphylococcus aureus Infection.

Andrew M Stoessel1, Cory M Hale2, Robert W Seabury1, Christopher D Miller1,3, Jeffrey M Steele1,3.   

Abstract

OBJECTIVE: This study aimed to assess the impact of area under the curve (AUC)-based vancomycin monitoring on pharmacist-initiated dose adjustments after transitioning from a trough-only to an AUC-based monitoring method at our institution.
METHODS: A retrospective cohort study of patients treated with vancomycin for complicated methicillin-resistant Staphylococcus aureus (MRSA) infection between November 2013 and December 2016 was conducted. The frequency of pharmacist-initiated dose adjustments was assessed for patients monitored via trough-only and AUC-based approaches for trough ranges: 10 to 14.9 mg/L and 15 to 20 mg/L.
RESULTS: Fifty patients were included: 36 in the trough-based monitoring and 14 in the AUC-based-monitoring group. The vancomycin dose was increased in 71.4% of patients when troughs were 10 to 14.9 mg/L when a trough-only approach was used and in only 25% of patients when using AUC estimation (P = .048). In the AUC group, the dose was increased only when AUC/minimum inhibitory concentration (MIC) <400; unchanged regimens had an estimated AUC/MIC ≥400. The AUC-based monitoring did not significantly increase the frequency of dose reductions when trough concentrations were 15 to 20 mg/L (AUC: 33.3% vs trough: 4.6%; P = .107).
CONCLUSIONS: The AUC-based monitoring resulted in fewer patients with dose adjustments when trough levels were 10 to 14.9 mg/L. The AUC-based monitoring has the potential to reduce unnecessary vancomycin exposure and warrants further investigation.

Entities:  

Keywords:  AUC; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring; vancomycin

Mesh:

Substances:

Year:  2018        PMID: 29554847     DOI: 10.1177/0897190018764564

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  7 in total

1.  Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-06-01

2.  Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Authors:  Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock
Journal:  Int J Clin Pharm       Date:  2021-04-28

3.  Gap Analysis for the Conversion to Area Under the Curve Vancomycin Monitoring in a Small Rural Hospital.

Authors:  Jennifer L Cole
Journal:  Fed Pract       Date:  2020-06

4.  Methods of Therapeutic Drug Monitoring to Guide Vancomycin Dosing Regimens: Trough Concentration versus Ratio of Area Under the Curve to Minimum Inhibitory Concentration.

Authors:  Ariane Du Sault; Marc Parent; Chantale Simard
Journal:  Can J Hosp Pharm       Date:  2022-04-04

5.  Vancomycin Dosing Practices among Critical Care Pharmacists: A Survey of Society of Critical Care Medicine Pharmacists.

Authors:  Alexander H Flannery; Drayton A Hammond; Douglas R Oyler; Chenghui Li; Adrian Wong; Andrew P Smith; Qiu Min Yeo; Whitney Chaney; Caitlin E Pfaff; Angela M Plewa-Rusiecki; Paul Juang
Journal:  Infect Dis (Auckl)       Date:  2020-09-25

6.  Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia or Pneumonia.

Authors:  Ryan Marko; Julia Hajjar; Vanessa Nzeribe; Michelle Pittman; Vincent Deslandes; Nadia Sant; Juthaporn Cowan; Kwadwo Kyermentang; Tim Ramsay; Sheryl Zelenitsky; Salmaan Kanji
Journal:  Can J Hosp Pharm       Date:  2021

7.  Individualized Vancomycin Dosing with Therapeutic Drug Monitoring and Pharmacokinetic Consultation Service: A Large-Scale Retrospective Observational Study.

Authors:  Sang-Mi Kim; Hyun-Seung Lee; Na-Young Hwang; Kyunga Kim; Hyung-Doo Park; Soo-Youn Lee
Journal:  Drug Des Devel Ther       Date:  2021-03-04       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.